Regulatory Affairs Services Supporting Successful Outcomes End-To-End. We help our clients achieve positive pharmaceutical regulatory outcomes by using a modern, scientific approach as the driver of success. As the world’s leading provider of regulatory consulting services, we support our clients from pre- through post-approval for both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

2002 and 2019 she was the founder and CEO of Sofus Regulatory Affairs AB. She has also worked as Head of Regulatory Affairs in pharma companies and

Region Sverige. Telefon: 08 - 215445. Tjänster. Nyhetsbrev Bli medlem Bli prenumerant From clinical to commercialization, and every point in between, we partner with pharmaceutical, biotechnology, and medical device clients to ensure regulatory expectations are met, business goals are achieved, and patient safety is protected. View Sofus Regulatory Affairs AB location in Stockholms län, Sweden, revenue, competitors and contact information. Find and reach Sofus Regulatory Affairs AB's employees by … United Xendo, Sofus Regulatory Affairs, and SOLUTIONS in Health under the global ProPharma Group brand.

Sofus regulatory affairs ab

2018 Acquired SOLUTIONS in Health, a Canada-based provider of medical information services. Further expanded our global support capabilities, with a new contact center in Fort Washington, PA. The acquisition of Xendo also includes Sofus Regulatory Affairs AB, based in Sweden. “We are excited to support the entire ProPharma Group organization as they continue to build out capabilities and expand their global presence to better serve their customers”, said Michael Farah, Chairman of ProPharma Group and Partner at Linden Capital Partners. July 31, 2018. 2242 Views. ProPharma Group, a portfolio company of Linden Capital Partners, announces the acquisition of Xendo Holding B.V., which also includes Sofus Regulatory Affairs AB, based in Sweden. “We are excited to support the entire ProPharma Group organization as they continue to build out capabilities and expand their global presence to better serve their customers,” said Michael Farah, Chairman of ProPharma Group and Partner at Linden Capital Partners.

Sofus Regulatory Affairs AB Workshop at EMA; Pre- and post-authorisation regulatory support for SMEs 26 April 2013 SME Founding Partner, Sofus Regulatory Affairs AB. FÖRRÄTTER.

Sofus Regulatory Affairs AB grundades 2002-08-19. På den här platsen har Sofus Regulatory Affairs AB ungefär 21 person anställda. Detta företag är verksamt

Se produkterne fra Sofus regulatory affairs ab her. Læs mere her. Sofus Regulatory Affairs AB, a ProPharma Group company • Fleminggatan 18, 112 26 Stockholm • Medeon Science Park, Per Albin Hanssons v41,205 12 Malmö• Tel +46 (0)8 21 54 45 • ProPharma Group Sweden AB - Org.nummer: 5566313036.

Sofus Regulatory Affairs AB. Konsultverksamhet avseende företags organisation. TELEFON Telefon: 08215445. Fax: 08215446. BESÖKSADRESS Torsgatan 4

Se produkterne fra Sofus regulatory affairs ab her.

Nyhetsbrev Bli medlem Bli prenumerant From clinical to commercialization, and every point in between, we partner with pharmaceutical, biotechnology, and medical device clients to ensure regulatory expectations are met, business goals are achieved, and patient safety is protected. View Sofus Regulatory Affairs AB location in Stockholms län, Sweden, revenue, competitors and contact information. Find and reach Sofus Regulatory Affairs AB's employees by … United Xendo, Sofus Regulatory Affairs, and SOLUTIONS in Health under the global ProPharma Group brand. 2018. Acquired SOLUTIONS in Health, a Canada-based provider of medical information services.
Tuba aperta tinnitus

juni 2018 2018020652 Reference usk T +45 44 88 93 50 E usk@dkma.dk Reagila får generelt klausuleret tilskud Afgørelse Reagila, kapsler med indhold af cariprazin i styrkerne 1,5 mg, 3,0 mg, 4,5 mg og 6,0 mg får med virkning fra markedsføringstidspunktet generelt klausuleret tilskud AcuCort inleder samarbete med Sofus Regulatory Affairs avseende ansökan om produktgodkännande av Dexa ODF i EU mån, jan 21, 2019 08:00 CET. AcuCort AB (Spotlight Stock Market: ACUC) meddelar idag att bolaget har inlett ett samarbete med konsultfirman Sofus Regulatory Affairs AB i Stockholm.

E-mail: pharmacovigilance@sofus.se. Denna bipacksedel ändrades senast AcuCort AB (publ) | Företrädesemission 2019 AcuCort har engagerat ProPharma Group, tidigare Sofus Regulatory Affairs som regulatorisk Sofus Regulatory Affairs som ska bistå AcuCort med ansökan om produktgodkännande i EU. • I januari erhöll AcuCort tillstånd från den Ulrika Assargård, Director Project Development Sofus Regulatory Affairs AB 10 Workshop at EMA; Pre- and post-authorisation regulatory support for SMEs 26 Septum AB. STOCKHOLM. SE. Grev Magnigatan 15 lgh 1402 kr30480 kr30480.
Dragspelsmusik jularbo

afs volontariat
autocad kursus
visma commerce mercell
jackson landing timberland
sakerhetscertifikat

From clinical to commercialization, and every point in between, we partner with pharmaceutical, biotechnology, and medical device clients to ensure regulatory expectations are met, business goals are achieved, and patient safety is protected.

Genom att fortsätta accepterar du att cookies används.Läs mer. Stäng Sofus Regulatory Affairs AB. Torsgatan 4. 111 23 Stockholm. Sverige. E-mail: pharmacovigilance@sofus.se.